Archit Organosys

{
  "main_header": {
    "sid": 849091,
    "name": "Archit Organosys",
    "stock_name": "Archit Organosys",
    "full_name": "Archit Organosys Ltd",
    "name_url": "stocks-analysis/archit-organosys",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "41.98",
    "chg": -0.78,
    "chgp": "-1.82%",
    "dir": -1,
    "prev_price": "42.76",
    "mcapval": "88.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524640,
    "symbol": "",
    "ind_name": "Commodity Chemicals",
    "ind_code": 11,
    "indexname": "",
    "isin": "INE078I01011",
    "curr_date": "Jan 19",
    "curr_time": "",
    "bse_nse_vol": "1.54 k",
    "exc_status": "Active",
    "traded_date": "Jan 19, 2026",
    "traded_date_str": "2026 01 19",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/archit-organosys-849091-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Archit Organosys Ltd Downgraded to Strong Sell Amid Technical and Fundamental Concerns",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/archit-organosys-ltd-downgraded-to-strong-sell-amid-technical-and-fundamental-concerns-3789383",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/ArchitOrganosys_mojoScore_3789383.png",
        "date": "2026-01-12 08:06:10",
        "description": "Archit Organosys Ltd, a player in the commodity chemicals sector, has seen its investment rating downgraded from Sell to Strong Sell as of 9 January 2026. This revision reflects a deterioration in technical indicators, persistent fundamental weaknesses, and valuation concerns despite recent positive quarterly financial results. The downgrade signals heightened caution for investors amid mixed signals across quality, valuation, financial trends, and technical analysis."
      },
      {
        "title": "Archit Organosys Ltd Upgraded to Sell on Technical Improvements Despite Lingering Fundamental Concerns",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/archit-organosys-ltd-upgraded-to-sell-on-technical-improvements-despite-lingering-fundamental-concerns-3778205",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/ArchitOrganosys_mojoScore_3778205.png",
        "date": "2026-01-02 08:07:16",
        "description": "Archit Organosys Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 1 January 2026, driven primarily by improvements in its technical indicators. While the company continues to face challenges in long-term fundamentals and valuation metrics, recent positive financial results and a shift in technical trends have prompted a reassessment of its market stance."
      },
      {
        "title": "Archit Organosys Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/archit-organosys-ltd-is-rated-strong-sell-3769551",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/ArchitOrganosys_mojoScore_3769551.png",
        "date": "2025-12-25 15:13:16",
        "description": "Archit Organosys Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 23 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 December 2025, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance."
      },
      {
        "title": "Archit Organosys Forms Death Cross, Signalling Potential Bearish Trend",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/archit-organosys-forms-death-cross-signalling-potential-bearish-trend-3765966",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/ArchitOrganosys_dealthcross_3765966.png",
        "date": "2025-12-22 18:01:48",
        "description": "Archit Organosys, a micro-cap player in the Commodity Chemicals sector, has recently formed a Death Cross, a technical pattern where the 50-day moving average crosses below the 200-day moving average. This development often signals a shift towards a bearish trend and suggests a weakening momentum in the stock’s price trajectory over the longer term."
      },
      {
        "title": "Archit Organosys Sees Revision in Market Evaluation Amidst Challenging Commodity Chemicals Sector",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/archit-organosys-downgraded-to-sell-by-marketsmojo-amid-weak-fundamentals-3749838",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/ArchitOrganosys_mojoScore_3749838.png",
        "date": "2025-12-06 10:10:23",
        "description": "Archit Organosys, a microcap player in the commodity chemicals sector, has undergone a revision in its market evaluation reflecting shifts in its fundamental and technical outlook. This adjustment follows a period marked by subdued returns and a cautious market stance, underscoring the complexities faced by smaller companies in this segment."
      },
      {
        "title": "Why is Archit Organosys falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-archit-organosys-fallingrising-3736108",
        "imagepath": "",
        "date": "2025-11-29 00:42:50",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Short-Term Gains Amidst Broader Challenges</strong></p>\n<p>Despite the recent rise, Archit Organosys has struggled to keep pace with the broader market. Over the past week, the stock declined by 1.02%, while the Sensex advanced by 0.56%. The divergence is more pronounced over longer periods, with the stock falling 8.77% in the last month compared to a 1.27% gain in the Sensex. Year-to-date, Archit Organosys is down 12.72%, whereas the benchmark index has appreciated by 9.68%. This trend extends further back, with the stock underperforming the Sensex by a wide margin over one, three, and five-year periods.</p>\n<p>However, the recent three-day rally, which has delivered a cumulative return of 6.92%, indicates a potential shift in investor sentiment. This short-term strength is supported by ris..."
      },
      {
        "title": "Archit Organosys Q2 FY26: Profitability Under Pressure as Margins Collapse",
        "link": "https://www.marketsmojo.com/news/result-analysis/archit-organosys-q2-fy26-profitability-under-pressure-as-margins-collapse-3713377",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/ArchitOrganosys_quaterlyResult_3713377.png",
        "date": "2025-11-14 09:36:16",
        "description": "Archit Organosys Ltd., a micro-cap commodity chemicals manufacturer, is navigating turbulent waters as its latest quarterly results reveal a sharp deterioration in operational efficiency. The company, with a market capitalisation of ₹92.00 crores, faces mounting challenges despite reporting improved topline growth in recent quarters."
      },
      {
        "title": "Is Archit Organosys overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-archit-organosys-overvalued-or-undervalued-3700240",
        "imagepath": "",
        "date": "2025-11-14 08:11:46",
        "description": "As of 13 November 2025, Archit Organosys' valuation grade has moved from attractive to fair. The company appears to be overvalued based on its current metrics. Notable ratios include a PE ratio of 147.70, an EV to EBITDA of 18.19, and a PEG ratio of 0.01, which suggests a significant disparity in growth expectations relative to its price.\n\nIn comparison to peers, Archit Organosys' PE ratio is substantially higher than that of Godrej Industries at 37.09, which is rated attractive, and Aarti Industries at 53.04, also rated fair. The company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -6.00% compared to the Sensex's 8.11%, further reinforcing the notion that Archit Organosys is currently overvalued...."
      },
      {
        "title": "How has been the historical performance of Archit Organosys?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-archit-organosys-3699047",
        "imagepath": "",
        "date": "2025-11-13 23:21:18",
        "description": "Answer:\nThe historical performance of Archit Organosys shows a declining trend in net sales and profits over the past few years.\n\nBreakdown:\nArchit Organosys reported net sales of 113.19 Cr in March 2024, a decrease from 127.78 Cr in March 2023 and 137.90 Cr in March 2022. The total operating income mirrored this decline, remaining at 113.19 Cr in March 2024 compared to 127.78 Cr in the previous year. The total expenditure, excluding depreciation, also decreased to 106.45 Cr in March 2024 from 108.90 Cr in March 2023. Operating profit (PBDIT) fell significantly to 9.18 Cr in March 2024 from 20.74 Cr in March 2023, reflecting a decrease in the operating profit margin from 14.78% to 5.95%. Profit before tax dropped to 4.32 Cr in March 2024, down from 15.36 Cr in March 2023, leading to a profit after tax of 3.28 Cr compared to 11.35 Cr the previous year. The earnings per share also declined to 1.6 in March 202..."
      }
    ],
    "total": 110,
    "sid": "849091",
    "stock_news_url": "https://www.marketsmojo.com/news/archit-organosys-849091"
  },
  "announcements": [
    {
      "caption": "Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011",
      "datetime": "29-Dec-2025",
      "details": "The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Suchit Amin & PACs",
      "source": "BSE"
    },
    {
      "caption": "Closure of Trading Window",
      "datetime": "27-Dec-2025",
      "details": "Intimation for closure of trading window for the quarter ended on 31st December 2025",
      "source": "BSE"
    },
    {
      "caption": "Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011",
      "datetime": "26-Dec-2025",
      "details": "The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Suchit Amin & PAC",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Archit Organosys Ltd has declared <strong>5%</strong> dividend, ex-date: 22 Sep 25",
          "dt": "2025-09-22",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "",
      "data": [
        {
          "txt": "Archit Organosys Ltd has announced <strong>2:1</strong> rights issue, ex-date: 09 Feb 17",
          "dt": "2017-02-09",
          "middle_text": "Rights Issue"
        }
      ]
    }
  ]
}

News and Views

Archit Organosys Ltd Downgraded to Strong Sell Amid Technical and Fundamental Concerns

2026-01-12 08:06:10

Archit Organosys Ltd, a player in the commodity chemicals sector, has seen its investment rating downgraded from Sell to Strong Sell as of 9 January 2026. This revision reflects a deterioration in technical indicators, persistent fundamental weaknesses, and valuation concerns despite recent positive quarterly financial results. The downgrade signals heightened caution for investors amid mixed signals across quality, valuation, financial trends, and technical analysis.

Read full news article

Archit Organosys Ltd Upgraded to Sell on Technical Improvements Despite Lingering Fundamental Concerns

2026-01-02 08:07:16

Archit Organosys Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 1 January 2026, driven primarily by improvements in its technical indicators. While the company continues to face challenges in long-term fundamentals and valuation metrics, recent positive financial results and a shift in technical trends have prompted a reassessment of its market stance.

Read full news article

Archit Organosys Ltd is Rated Strong Sell

2025-12-25 15:13:16

Archit Organosys Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 23 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 December 2025, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance.

Read full news article

Archit Organosys Forms Death Cross, Signalling Potential Bearish Trend

2025-12-22 18:01:48

Archit Organosys, a micro-cap player in the Commodity Chemicals sector, has recently formed a Death Cross, a technical pattern where the 50-day moving average crosses below the 200-day moving average. This development often signals a shift towards a bearish trend and suggests a weakening momentum in the stock’s price trajectory over the longer term.

Read full news article

Archit Organosys Sees Revision in Market Evaluation Amidst Challenging Commodity Chemicals Sector

2025-12-06 10:10:23

Archit Organosys, a microcap player in the commodity chemicals sector, has undergone a revision in its market evaluation reflecting shifts in its fundamental and technical outlook. This adjustment follows a period marked by subdued returns and a cautious market stance, underscoring the complexities faced by smaller companies in this segment.

Read full news article

Why is Archit Organosys falling/rising?

2025-11-29 00:42:50

Short-Term Gains Amidst Broader Challenges

Despite the recent rise, Archit Organosys has struggled to keep pace with the broader market. Over the past week, the stock declined by 1.02%, while the Sensex advanced by 0.56%. The divergence is more pronounced over longer periods, with the stock falling 8.77% in the last month compared to a 1.27% gain in the Sensex. Year-to-date, Archit Organosys is down 12.72%, whereas the benchmark index has appreciated by 9.68%. This trend extends further back, with the stock underperforming the Sensex by a wide margin over one, three, and five-year periods.

However, the recent three-day rally, which has delivered a cumulative return of 6.92%, indicates a potential shift in investor sentiment. This short-term strength is supported by ris...

Read full news article

Archit Organosys Q2 FY26: Profitability Under Pressure as Margins Collapse

2025-11-14 09:36:16

Archit Organosys Ltd., a micro-cap commodity chemicals manufacturer, is navigating turbulent waters as its latest quarterly results reveal a sharp deterioration in operational efficiency. The company, with a market capitalisation of ₹92.00 crores, faces mounting challenges despite reporting improved topline growth in recent quarters.

Read full news article

Is Archit Organosys overvalued or undervalued?

2025-11-14 08:11:46

As of 13 November 2025, Archit Organosys' valuation grade has moved from attractive to fair. The company appears to be overvalued based on its current metrics. Notable ratios include a PE ratio of 147.70, an EV to EBITDA of 18.19, and a PEG ratio of 0.01, which suggests a significant disparity in growth expectations relative to its price. In comparison to peers, Archit Organosys' PE ratio is substantially higher than that of Godrej Industries at 37.09, which is rated attractive, and Aarti Industries at 53.04, also rated fair. The company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -6.00% compared to the Sensex's 8.11%, further reinforcing the notion that Archit Organosys is currently overvalued....

Read full news article

How has been the historical performance of Archit Organosys?

2025-11-13 23:21:18

Answer: The historical performance of Archit Organosys shows a declining trend in net sales and profits over the past few years. Breakdown: Archit Organosys reported net sales of 113.19 Cr in March 2024, a decrease from 127.78 Cr in March 2023 and 137.90 Cr in March 2022. The total operating income mirrored this decline, remaining at 113.19 Cr in March 2024 compared to 127.78 Cr in the previous year. The total expenditure, excluding depreciation, also decreased to 106.45 Cr in March 2024 from 108.90 Cr in March 2023. Operating profit (PBDIT) fell significantly to 9.18 Cr in March 2024 from 20.74 Cr in March 2023, reflecting a decrease in the operating profit margin from 14.78% to 5.95%. Profit before tax dropped to 4.32 Cr in March 2024, down from 15.36 Cr in March 2023, leading to a profit after tax of 3.28 Cr compared to 11.35 Cr the previous year. The earnings per share also declined to 1.6 in March 202...

Read full news article

View All News